43 completed, 16 unknown, 13 terminated, 11 recruiting. 96 Phase 2, 11 Phase 3, 9 Phase 1.
Follow Mitomycin: new trials by email Literature Review of Mitomycin trials Research Report on Mitomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer Enfortumab vedotin, Pembrolizumab, Cisplatin - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 70 | 2026-10-16 | 2026-11-02 |
| Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis Cisplatin, Mitomycin C - Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis | Phase 2 | Recruiting | Mohammad Haroon Asif Choudry | 22 | 2026-09-29 | 2026-10-22 |
| Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors Gemcitabine, Mitomycin C, Thalidomide - Solid Tumor Cancer | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 60 | 2026-06-01 | 2026-06-26 |
| Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer Cisplatin, Mitomycin - Gastric Cancer, Peritoneal Carcinomatosis | Phase 2 | Recruiting | University of Chicago | 21 | 2025-09-09 | 2026-09-08 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2025-06-03 | 2026-10-19 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial BCG Solution, Cystoscopy, Docetaxel - Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 40 | 2025-04-21 | 2026-10-08 |
| The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy Mitomycin-C, gemcitabine - Bladder Cancer | Phase 2 | Recruiting | National Cancer Center, Korea | 82 | 2024-11-19 | 2026-05-29 |
| Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin, Mitomycin C (MMC) - Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 2 | Recruiting | Shanxi Province Cancer Hospital | 50 | 2024-04-01 | 2026-11-03 |
| Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer G-GLIP plus Mitomycin C - Pancreatic Cancer | Phase 2 | Not yet recruiting | Hirschfeld Oncology | 60 | 2024-03-15 | 2024-02-28 |
| REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c - Anal Cancer | Phase 2 / Phase 3 | Active not recruiting | University of Cincinnati | 33 | 2023-08-14 | 2025-12-18 |
| Phase II Trial of Lung Chemoemobolization Computed Tomography, Ethiodized Oil, Mitomycin - Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm | Phase 2 | Recruiting | City of Hope Medical Center | 30 | 2023-05-12 | 2026-03-05 |
| Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords Curcumin, Mitomycin-C - Glottic Web of Larynx, Laryngeal Stenosis | Phase 1 / Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 100 | 2023-05-05 | 2023-05-06 |
| Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive | Phase 2 | Active not recruiting | Roland Seiler-Blarer | 31 | 2023-02-21 | 2026-07-13 |
| Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Mitomycin, Lobaplatin - Colorectal Cancer, Chemotherapy Effect | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 201 | 2022-09-01 | 2022-02-21 |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Anoscopy, Biospecimen Collection, Capecitabine - AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2022-08-09 | 2026-10-05 |
| Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture Mitomycin c - Urethral Stricture | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2022-01-01 | 2024-01-30 |
| Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2 - Peritoneal Carcinomatosis | Phase 2 | Recruiting | Prakash Pandalai | 100 | 2021-06-04 | 2026-04-01 |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Biopsy of Bladder, Biospecimen Collection, Cisplatin - Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2021-03-17 | 2026-05-22 |
Showing 20 of 96. Sign in to see all of them.
Urinary Bladder Neoplasms (18) · Colorectal Neoplasms (11) · Neoplasm Metastasis (10) · Non-Muscle Invasive Bladder Neoplasms (10) · Anus Neoplasms (8) · Appendiceal Neoplasms (6) · Glaucoma (6) · Pancreatic Neoplasms (6) · Peritoneal Neoplasms (6) · Carcinoma, Hepatocellular (5) · Carcinoma, Transitional Cell (5) · Stomach Neoplasms (5) · Colonic Neoplasms (4) · Rectal Neoplasms (4) · Sarcoma (4)
National Cancer Institute (NCI) (4) · Fox Chase Cancer Center (3) · Mayo Clinic (3) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Gynecologic Oncology Group (2) · IRCCS San Raffaele (2) · M.D. Anderson Cancer Center (2) · Radiation Therapy Oncology Group (2) · Seoul National University Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · UNICANCER (2) · UroGen Pharma Ltd. (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Ain Shams University (1) · Albert Einstein College of Medicine (1)
United States (55) · China (8) · France (6) · Italy (6) · Belgium (4) · South Korea (4) · United Kingdom (4) · India (3) · Israel (3) · Netherlands (3) · Switzerland (3) · Australia (2) · Canada (2) · Egypt (2) · Germany (2)
Dominique Elias, MD (2) · Jung-Hwan Yoon, M.D., Ph.D. (2) · Adriaan D. Bins, MD PhD (1) · Aldo V. Bono, MD (1) · Alex W Yeung, MBBS (1) · Ardaman Shergill (1) · Azriel Hirschfeld, MD (1) · Brian C Baumann (1) · Brian D Badgwell (1) · Brian D. Badgwell, MD (1) · Carsten Bokemeyer, MD (1)
PMID 34125951, PMID 41074972, PMID 12051882, PMID 16051328, PMID 17470859, PMID 19171491, PMID 19643599, PMID 20354452, PMID 20570237, PMID 21135251, PMID 21156335, PMID 22287157, PMID 22831982, PMID 23510863, PMID 24362862, PMID 25019269, PMID 25680955, PMID 25954110, PMID 27519353, PMID 27633880, PMID 28643069, PMID 29189540, PMID 30247524, PMID 32067679, PMID 32124514, PMID 32306237, PMID 32556731, PMID 33660142, PMID 34051177, PMID 34433303, PMID 35640276, PMID 36410913, PMID 37170307, PMID 37596191, PMID 37611799, PMID 37690994, PMID 38265030, PMID 38740030, PMID 39226514, PMID 39680823
U10CA180820 (2), 2019 (1), 2023 (1), P30CA006973 (1), P30CA015083 (1), P30CA033572 (1), U10CA021115 (1), U10CA032102 (1), U10CA180868 (1), UL1TR002377 (1), UM1CA121947 (1)